Integrated Multi-omics Data for Personalized Treatment of Obesity-associated Fatty Liver Disease

Launched by INSTITUT INVESTIGACIO SANITARIA PERE VIRGILI · Sep 23, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how to better understand and treat obesity-related fatty liver disease, which can occur when there’s too much fat in the liver, often linked to obesity and diabetes. Researchers want to analyze samples from patients to find out how different factors—like genetics and health conditions—affect this disease. They aim to use advanced technology, including artificial intelligence, to create models that help predict how this condition develops and how it can be treated more effectively.

To participate in this study, you need to be at least 18 years old and have a body mass index (BMI) of 40 or higher. If your BMI is between 35 and 40, you can still join if you have certain health issues like high blood pressure or diabetes. However, there are some exclusions: if you have a history of drug or alcohol abuse, liver disease like hepatitis, or currently have cancer or severe infections, you wouldn't be eligible. Participants can expect to provide samples and answer questions about their health, contributing to important research that may lead to better treatments for fatty liver disease in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Body mass index greater or equal to 40 kg/m\^2.
• • Body mass index between 35 and 40 kg/m\^2 with high-risk comorbidities (diagnosis or treatment for hypertension, dyslipidemia, or type 2 diabetes mellitus).
• • Positive psychiatric evaluation.
• • Age greater or equal to 18 years old.
• Exclusion Criteria:
• • Legal or illegal drug consumption, including alcohol.
• • Diagnosis of Hepatitis.
• • Current cancer diagnosis or treatment.
• • Clinical or analytical evidence of severe illness.
• • Clinical or analytical evidence of chronic or acute inflammation.
• • Clinical or analytical evidence of infectious diseases.
• • Clinical or analytical evidence of terminal illness.